

Terry Fox Research Institute (Quebec)

Our Focus

The TFRI (Quebec) wishes to fill a significant void in the translation from basic to clinical applications of cancer discoveries. Thus, the focus will be on translational applications of such areas as biomarkers, discovery and validation, the identification of new targets in cancer initiation, progression and metastasis, and the development of novel, small-molecule modulators in the treatments of all types of cancers.

To be funded by the TFRI (Quebec) projects must demonstrate the ability to address cancer-care issues and clinical improvements within three to five years. Also, projects funded by the Quebec node will require the involvement of basic and clinical scientists from at least two independent Quebec research institutions.

The TFRI (Quebec) has already reviewed nearly 20 independent cancer translation projects, several of which have been retained for funding and will be supported as they move toward clinical applications.

Our Members

The Terry Fox Research Institute (Quebec) consists of five cancer research institutions for the moment. The partners comprise the following institutions: McGill Cancer Centre, Segal Cancer Centre, Centre Hospitalier Universitaire de Montréal (CHUM), l'Institut de Recherche Clinique de Montréal, and the McGill University Health Centre (MUHC). In addition to working with cancer researchers in Quebec research institutions, partnerships will also be developed with leading cancer research foundations and institutes elsewhere in Quebec. To date, the Fondation de la recherche en santé du Québec (FRSQ), le Programme de Lutte contre le Cancer and the Cancer Research Society have expressed interest in participating in the programs of the TRFI (Quebec) node.

Cancer scientists and clinicians from other Quebec universities and research centres are encouraged to participate in the research programs of the TFRI (Quebec).

Coordinators of the Terry Fox Research Institute (Quebec) Node

The TFRI (QC) node is coordinated by Drs. Anne-Marie Mes-Masson and Michel L. Tremblay.

Dr. Anne-Marie Mes-Masson

Dr. Mes-Masson is the Scientific Director of the Institut du cancer de Montréal, the cancer research arm of the CHUM Research Institute, and the FRSQ cancer network. Dr. Mes-Masson's research involves the identification of key markers of ovarian and prostate cancers and their therapeutic applications.

Dr. Michel L. Tremblay

Dr. Tremblay is the Director of the McGill Cancer Centre at McGill University in Montreal. Holder of the Jeanne and Jean-Louis Lévesque Chair in Cancer Research, he heads the Quebec Transgenic Research Network and is a member of the Executive Committee of the FRSQ. He is engaged in the discovery of tumour suppressors and oncogenes and their modulation through small molecules.